{"id":"W3003274437","doi":"10.1016/j.jaad.2020.01.056","title":"Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"LEO Pharma; MedImmune; Galderma; Ortho Dermatologics; Dermira; DUSA Pharmaceuticals; Vanda Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Kiniksa Pharmaceuticals; AbbVie; Sun Pharma; Regeneron Pharmaceuticals; Abbott Laboratories; Sanofi; Novartis; Pfizer; Amgen","keywords":"Medicine; Double blind; Placebo; Dermatology; Randomized controlled trial; Clinical trial; Internal medicine; Alternative medicine; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001871879,0.002539343,0.004345655,0.000656906,0.0006006125,0.001366283,0.001260572,0.003133221,0.01264403],"category_scores_gemma":[0.001774995,0.0009640933,0.0020987,0.0005392953,0.001553322,0.001782202,0.000437456,0.003704865,0.001934028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000625417,"about_ca_system_score_gemma":0.001029277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008660409,"about_ca_topic_score_gemma":0.001944688,"domain_scores_codex":[0.999383,0.0002618647,0.00003256319,0.0001480992,0.00005421903,0.0001203277],"domain_scores_gemma":[0.9993497,0.0001982737,0.0001216447,0.0000513643,0.00004868861,0.0002303067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9790693,0.005010891,0.0001604757,0.001220462,0.0007213684,0.00004862271,0.00004216944,0.0001866936,0.002474343,0.0001411487,0.001048674,0.009875879],"study_design_scores_gemma":[0.9841814,0.01486605,0.0002942285,0.00002030946,0.0001477173,0.00001477826,0.000008211147,0.000101513,0.00008229363,0.00005987914,0.0002174723,0.000006251551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9561058,0.01844625,0.002229334,0.002272988,0.002409928,0.01044665,0.002295667,0.0006644379,0.005129054],"genre_scores_gemma":[0.9646595,0.009811862,0.003189563,0.003106699,0.001155469,0.008704576,0.001756345,0.00007920282,0.007536915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01264403,"threshold_uncertainty_score":0.0422985,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06953297999972495,"score_gpt":0.3760347833045655,"score_spread":0.3065018033048405,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}